-
1 Comment
OKYO Pharma Limited is currently in a long term downtrend where the price is trading 25.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-435K since the same quarter in the previous year.
Finally, its free cash flow grew by 47.9% to $-215K since the same quarter in the previous year.
Based on the above factors, OKYO Pharma Limited gets an overall score of 2/5.
| Industry | |
|---|---|
| ISIN | GG00BD3FV870 |
| Sector | |
| Exchange | LSE |
| CurrencyCode | GBP |
| Beta | -0.06 |
|---|---|
| Market Cap | 23M |
| PE Ratio | None |
| Target Price | 26029.2 |
| Dividend Yield | 0.0% |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OKYO.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
